208 results
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
, which is designed for cancers with FGFR2 and FGFR3 alterations. Kinnate also has early-stage programs, including a c-MET inhibitor that targets resistant
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
, an investigational pan-RAF inhibitor which targets cancers with BRAF and NRAS-driven alterations, was one of Kinnate’s lead product candidates. Kinnate’s other lead … early-stage programs, including a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. For more information
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
inhibitor that targets resistant variants and a brain penetrant CDK4 selective program.
Kinnate was incorporated under the laws of the State of Delaware
SC TO-C
EX-99.1
KNTE
Kinnate Biopharma Inc
27 Feb 24
Information about tender offer
4:42pm
, which targets cancers with BRAF and NRAS-driven alterations, and investigational FGFR inhibitor, KIN-3248, which is designed for cancers with FGFR2 … and FGFR3 alterations. Kinnate also has early stage programs, including a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4
8-K
EX-99.1
boq85eocoak61i
16 Feb 24
XOMA Enters into Agreement to Acquire Kinnate Biopharma
9:08am
8-K
q1pfr2
16 Feb 24
XOMA Enters into Agreement to Acquire Kinnate Biopharma
9:08am
8-K
EX-99.1
55mb vggv7tzx
11 Dec 20
Entry into a Material Definitive Agreement
5:27pm